-
2024-518962-29-00
4
2021-12-07
Spinocerebellar ataxia type 7 (SCA7)
-
2024-516330-35-00
5
2021-09-29
Non-Small Cell Lung Cancer
-
2023-510433-29-00
5
2020-09-24
Favorable-intermediate-risk Acute Myeloid Leukemia
-
2024-517864-49-01
5
2020-09-08
Autosomal Dominant Polycystic Kidney Disease
-
2023-507885-21-00
4
2020-08-18
Chronic Inflammatory Demyelinating Polyneuropathy
-
2024-513372-18-00
4
2019-10-18
Pre- and post-menopausal women with HR+/HER2- LABC or MBC whose diseas
-
2023-504520-26-00
5
2017-10-19
Duchenne Muscular Dystrophy (DMD)
-
2024-518869-99-00
4
2025-11-17
Cushing's disease
-
2024-516473-72-00
5
2025-07-31
Multifocal Motor Neuropathy
-
2023-508095-11-00
5
2024-11-27
Childhood Absence Epilepsy
-
2023-508636-61-00
5
2024-10-24
Crohn’s Disease
-
2023-508670-28-00
5
2024-08-26
Hypertension
-
2023-506669-70-00
5
2024-04-30
Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
-
2023-504413-80-00
5
2023-12-07
Obesity
-
2022-502779-40-00
5
2023-09-04
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-511654-42-00
5
2023-06-28
Spinal Muscular Atrophy (SMA)
-
2023-505552-22-00
5
2023-02-24
Stage I-III Triple-negative Breast Cancer with residual invasive disea
-
2023-504741-32-00
4
2022-11-30
Moderately to Severely Active Crohn's Disease
-
2023-504743-13-00
4
2022-11-30
Moderately to Severely Active Ulcerative Colitis
-
2024-515637-14-00
5
2022-11-08
Cystic Fibrosis
-
2024-515557-22-00
6
2022-10-01
Juvenile Idiopathic Arthritis
-
2024-514630-21-00
4
2022-08-11
HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
-
2024-518304-53-00
5
2022-02-02
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2023-509372-41-00
5
2022-01-30
Multiple Sclerosis